Abstract

Trypanosoma cruzi has three distinct life cycle stages; epimastigote, trypomastigote, and amastigote. Amastigote is the replication stage in host mammalian cells, hence this stage of parasite has clinical significance in drug development research. Presence of extracellular amastigotes (EA) and their infection capability have been known for some decades. Here, we demonstrate that EA can be utilized as an axenic culture to aid in stage-specific study of T. cruzi. Amastigote-like property of axenic amastigote can be sustained in LIT medium at 37°C at least for 1 week, judging from their morphology, amastigote-specific UTR-regulated GFP expression, and stage-specific expression of selected endogenous genes. Inhibitory effect of benznidazole and nifurtimox on axenic amastigotes was comparable to that on intracellular amastigotes. Exogenous nucleic acids can be transfected into EA via conventional electroporation, and selective marker could be utilized for enrichment of transfectants. We also demonstrate that CRISPR/Cas9-mediated gene knockout can be performed in EA. Essentiality of the target gene can be evaluated by the growth capability of the knockout EA, either by continuation of axenic culturing or by host infection and following replication as intracellular amastigotes. By taking advantage of the accessibility and sturdiness of EA, we can potentially expand our experimental freedom in studying amastigote stage of T. cruzi.

Highlights

  • Trypanosoma cruzi is the causative agent of Chagas’ disease, which affects 6–7 million people mainly in Latin America[1]

  • We developed an experimental system to study amastigote stage of Trypanosoma cruzi as a proliferable axenic culture

  • Gene knockout can be performed in amastigote-specific manner, using Cas9-expressing extracellular amastigotes

Read more

Summary

Introduction

Trypanosoma cruzi is the causative agent of Chagas’ disease, which affects 6–7 million people mainly in Latin America[1]. 30 to 40% of infected people develop chronic disease 10 to 30 years after acute infection[1]. There are currently two drugs available to treat Chagas’ disease; benznidazole and nifurtimox. Both drugs are effective in acute phase of the infection, but efficacy becomes limited once the disease proceeds to chronic phase[4]. Because most parasite carriers do not get a timely diagnosis or have access to the medication, many of them proceed to chronic phase unnoticed or without proper treatment. Development of safer new drugs that are effective in chronic phase is a pressing matter

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.